
YPD-30 has significant anticancer performance
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer ScienceDirect Cancer immunotherapy is a breakthrough for
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer ScienceDirect Cancer immunotherapy is a breakthrough for